The changing non-invasive fibrosis index value in patients with hepatitis C treated with direct-acting antiviral agents

Background and Aims: About 400 000 patients with hepatitis C virus die from cirrhosis-related complications hepatocellular carcinoma every year. Direct-acting antivirals provide a sustained virologic response in more than 90% of infection. We aimed to evaluate the alteration non-invasive fibrosis index who were treated direct-acting antivirals. Materials Method: Patients received complete course analyzed. FIB-4 APRI calculated for each patient. Results: Of 88 patients, 46 (52%) males, 21 (23.8%) cirrhotics. The mean age was 58 years. significant decrease showed scores compared baseline end treatment. There statistically drop post (p < 0.001). In long-term follow-up, it observed continue low at 15 months response. Mean follow up-time 27.8 ± 24.3 our study, just one patient diagnosed cancer after treatment during follow-up. Conclusion: An early decline can be related liver enzymes. Nonetheless, maintaining level markers has been linked reduction necroinflammation.